ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients (PICS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01213017
Recruitment Status : Completed
First Posted : October 1, 2010
Last Update Posted : December 7, 2017
Sponsor:
Collaborator:
UCB Pharma
Information provided by (Responsible Party):
Oklahoma Medical Research Foundation

Brief Summary:
The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: certolizumab pegol Phase 3

Detailed Description:
The primary objective of this study is to evaluate the efficacy of CSP used in combination with MTX in patients with active moderate to severe RA by evaluating change from baseline in synovitis and bone edema MRI scores at week 6.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients
Study Start Date : September 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : April 2012


Arm Intervention/treatment
Experimental: Certolizumab pegol Drug: certolizumab pegol
400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
Other Name: Cimzia



Primary Outcome Measures :
  1. the change from baseline in synovitis and bone edema RAMRIS score. [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. the change from baseline in RAMRIS erosion score [ Time Frame: 16 and 52 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • moderate to severe RA (DAS > 4.4)
  • at least two swollen and tender joints in one of the hand/ wrist
  • patients must have failed at least one non-biologic or biologic DMARDs
  • currently receiving MTX therapy

Exclusion Criteria:

  • concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01213017


Locations
United States, Florida
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, United States, 33180
United States, Oklahoma
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Oklahoma Medical Research Foundation
UCB Pharma
Investigators
Principal Investigator: Ewa Olech, MD Oklahoma Medical Research Foundation
Principal Investigator: Norman B Gaylis, MD Arthritis and Rheumatic Disease Specialties

Responsible Party: Oklahoma Medical Research Foundation
ClinicalTrials.gov Identifier: NCT01213017     History of Changes
Other Study ID Numbers: OMRF-UCB-5-16-2010
First Posted: October 1, 2010    Key Record Dates
Last Update Posted: December 7, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make individual participant data available

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Oklahoma Medical Research Foundation:
Certolizumab pegol
Magnetic Resonance Imaging
Rheumatoid Arthritis
RAPID 3

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Synovitis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Certolizumab Pegol
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents